This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 641549
As a result of expanding efforts to improve cancer therapy, a main paradigm change has occurred by targeting the immune system, not the tumor itself. „Science“ highlighted immunotherapy of cancer as „breakthrough of the year 2013“. Antibody-based therapies form an integral and constantly growing part of this approach leading towards individualised medicine. These therapies will strongly influence the coming decade of cancer care.
The training network for the immunotherapy of cancer (IMMUTRAIN), received 3,6 Mio.€ for four years from the European Union in order to perform cutting-edge research in this field and to respond to the increasing demand for well-trained and skilled researchers. The network is coordinated by Prof. Dr. Stefan Endres and PD Dr. Sebastian Kobold from the Division of Clinical Pharmacology at the Ludwig-Maximilians-Universität München. IMMUTRAIN will bring together experts of nine European countries in the fields of monoclonal antibodies, dendritic cells, T-cells and immunomodulatory nucleic acids. The network also offers a considerable industrial involvement to train the next generation of scientists from different perspectives and give insights in different research environments.
Training programme and scientific projects
The overall scientific objective of IMMUTRAIN is to enhance the efficacy of antibody-based therapies through combination with other immunotherapeutic approaches. Each Early Stage Researcher (ESR) is appointed for a scientific project by a partner of the network (host institution) and supervised by a one or more senior scientists (PI). Each project is part of one of the four scientific work packages of IMMUTRAIN.
IMMUTRAIN’s training objectives are: 1) To give an extensive overview of immunologic combination partners for antibodies. 2) To teach how to develop new therapies (target validation, drug discovery and development). 3) To provide a broad methodological know-how in the field of immunotherapy. 4) To provide transferable skills. 5) To give an insight into the respective chances and challenges of the academic and industrial sectors. 6) To provide academic and industry contacts for later cooperations and/or employment.
Call for applications
The IMMUTRAIN project is looking for one Early Stage Researcher (ESR) to join the training and research programme at Institut Gustave Roussy, Paris, France, under the supervision of Prof. Laurence Zitvogel. The research project of the ESR will be part of the work package 4, “Target discovery and validation for antibody combination therapies”.
Further Information: www.immutrain.eu
- Cutting-edge-research project
- State-of-the-art and innovative international training in one of the most exiting fields of biomedical research: cancer immunotherapy
- Project with strong translational perspective
- Excellent training and opportunities for future employment in academic and private sector
- An employment contract for maximum two years with all the benefits of the Marie Skłodowska-Curie programme:
- a living allowance (salary including e.g. social security)
- a mobility allowance
- a family allowance (if applicable).
- The application procedure will be carried out in compliance with the Code of Conduct for Recruitment and the Charter for Researchers
- Excellent scientists with a master degree or equivalent in natural sciences or related disciplines (such as medicine or pharmacy)
- Practical skills in modern laboratory work, preferentially combined with experience in animal experiments
- Be within your first four years of research experience after completion of your masters degree or equivalent
- Not have spent more than 12 months within the past 36 months in France (mobility rule)
- Not hold a doctoral degree at the time of recruitment
- Be proficient in the English language both written and spoken (proof required)
- Submit your full application before 19.11.2017
Please note that we will require the strict application of any of the “must” criteria prior to recruitment. If you fail to provide firm evidence for any of these criteria, you will be excluded from further consideration for the programme.
Applications will only be accepted and considered via the web portal. Applications will open on October 10th, 2017 and close on November 19th, 2017.
The applications will be evaluated in two steps:
- Step 1: Review of the applications by Institut Roussy based on the criteria of eligibility described in the section “you must”. Furthermore the selection will take into account the criteria listed in Code of conduct for the Recruitment of researchers and the European Charta for Researchers.
- Step 2: Selected candidate of step 1 will be invited for an interview with the team of Prof. Laurence Zitvogel.
The candidates will be informed about the results of the selection in December 2017.
For any questions or inquiries, please contact
Simone Gautier, Division of Clinical Pharmacology, Klinikum der Universität München
Welcome to our application site
The application form contains nine different tabs enabling you to enter all required information and to upload corresponding documents. To save entries please click the Save Button at the bottom of the page. Entries will not be saved automatically. You may revisit and modify your personal application form any time prior to final submission. When you are ready to submit your application, please click the Save and Submit Button. After submission you will no longer be able to edit your application. However, you will be able to view your submitted data throughout the application process. Submission of applications is only possible, if all required fields (marked with a yellow triangle) are filled out. Non required fields are optional but it is recommended to fill out all those fields that apply to your specific situation.
Letters of recommendation
It is strongly recommended to apply for the letters of recommendation as soon as possible. This will allow your mentors sufficient time to submit the letters in a timely manner. Please visit tab References for more information.
We only accept non-encrypted PDF files (recommended) or JPEG files. Uploads have a size restriction of 5 MB each. It is recommend to scan documents with 300dpi. If a document consists of more than one page please combine those pages into a single PDF document. IMPORTANT: Please make sure that your documents are NOT password protected or encrypted. Encrypted files can not be processed and hence will not be available to members of the admissions committee.
If you click on My Progress in the left menu, you will be able to see the current status of your application.
Your application file To view the final pdf file of your application please click on the tab "PDF", choose a template from the list and click on Download PDF. A pdf file will then be generated that is identical to the one, seen by the admissions committee (except the confidential letters of reference that will not be displayed in your version). Some of the fields you have filled out will not be displayed in this document (but will be stored in our data bank).
Deadline for submission of your application including the reference letters is 19.11.2017.
This call for applications is closed.